Respiratory and sleep disorders in mucopolysaccharidosis
Kenneth I. Berger(New York University), David M. Rapoport(Icahn School of Medicine at Mount Sinai), Simone Chaves Fagondes(Hospital de Clínicas de Porto Alegre), Karen Hardy, Martin J. Tobin(University of Leicester), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Susan A. Ward, Ciarán B. McArdle(Birmingham Children's Hospital), Kuo Sheng Lee(Mackay Memorial Hospital), Maurizio Scarpa(Unknown)
Cited by 158
Related Papers
Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery
|CHEST Journal|2013|901
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307